GH Research (NASDAQ:GHRS) Given New $70.00 Price Target at HC Wainwright

GH Research (NASDAQ:GHRS) had its target price upped by HC Wainwright from $35.00 to $70.00 in a research report report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages have also recently commented on GHRS. Canaccord Genuity Group boosted their price target on shares of GH Research from $35.00 to $39.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Thursday, January 22nd. Guggenheim reissued a “buy” rating and set a $29.00 price target on shares of GH Research in a research report on Monday, January 5th. Citigroup reissued a “market outperform” rating on shares of GH Research in a report on Tuesday, January 6th. Finally, Wall Street Zen downgraded shares of GH Research from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $38.75.

GH Research Stock Up 7.8%

Shares of GHRS opened at $16.01 on Monday. GH Research has a twelve month low of $7.98 and a twelve month high of $19.51. The stock has a market capitalization of $832.97 million, a P/E ratio of -21.63 and a beta of 0.99. The company has a 50 day moving average of $15.23 and a 200-day moving average of $14.18.

Hedge Funds Weigh In On GH Research

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new stake in GH Research in the 2nd quarter valued at $79,000. Virtus Investment Advisers LLC bought a new stake in shares of GH Research in the second quarter valued at about $89,000. Stempoint Capital LP bought a new stake in shares of GH Research in the second quarter valued at about $1,229,000. HighVista Strategies LLC acquired a new position in shares of GH Research in the second quarter valued at about $637,000. Finally, BNP Paribas Financial Markets increased its position in GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after acquiring an additional 10,600 shares during the period. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.